Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors-Reference-Cited by-同舟云学术

Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors

Published:2021-03-24 Issue:586 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Liu Yue¹²^ORCID,Liu Guangna¹^ORCID,Wang Jiasheng¹²^ORCID,Zheng Zhe-yu¹^ORCID,Jia Lemei¹^ORCID,Rui Wei³^ORCID,Huang Daosheng¹^ORCID,Zhou Zhi-xiao¹²^ORCID,Zhou Liqun¹^ORCID,Wu Xin¹^ORCID,Lin Song⁴^ORCID,Zhao Xueqiang¹^ORCID,Lin Xin¹²^ORCID

Affiliation:

1. Institute for Immunology and School of Medicine, Tsinghua University, Beijing 100084, China.

2. Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.

3. China Immunotech (Beijing) Biotechnology Co., Ltd, Beijing 102206, China.

4. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.

Abstract

T cells engineered with synthetic receptors that integrate components of T cell and B cell receptors show efficacy against solid tumors in mice.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China Stem Cell and Translational Research

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference49 articles.

1. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

2. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

3. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

4. Prospects for gene-engineered T cell immunotherapy for solid cancers

5. The Principles of Engineering Immune Cells to Treat Cancer

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation;Science Advances;2024-09-06

2. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights;Frontiers in Immunology;2024-09-05

3. T cell exhaustion in human cancers;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review;European Journal of Cancer;2024-09

5. TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models;Molecular Therapy: Oncology;2024-09